ASX:NEUPharmaceuticals
Neuren Pharmaceuticals (ASX:NEU): Assessing Valuation After FDA Fast Track Win for Rare Disease Therapy
Neuren Pharmaceuticals (ASX:NEU) caught attention after announcing its candidate NNZ-2591 received Fast Track designation from the US FDA for both Phelan-McDermid and Angelman syndromes. This status could help accelerate development and review timelines.
See our latest analysis for Neuren Pharmaceuticals.
Neuren’s Fast Track milestones have fueled fresh momentum, with the share price climbing 79% year-to-date and a remarkable 5-year total shareholder return nearing 2,000%. These advances come...